Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines. Ida N, Okura M, Tanaka S, Hosono N, et al. Int J Hematol 2026;124:348-360.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ida N, Okura M, Tanaka S, Hosono N, et al. Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines. Int J Hematol 2026;124:348-360.
PMID: 42115534